Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity

APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
Wenzhong QueDanrong Jiang

Abstract

The c-Met is a receptor tyrosine kinase that is overexpressed in human myeloma cell lines and promotes the survival and drug resistance of myeloma cells. This study aimed to elucidate the mechanisms by which c-Met contributes to the chemoresistance in myeloma. Stable U266 cell line in which c-Met was effectively knockdown was employed and treated with bortezomib. Cytotoxicity was evaluated by MTT assay. Cell cycle profile and apoptosis were examined by cytometry analysis. The expression of cell cycle related proteins, and the activities of caspases and Akt/mTOR were detected by Western blot analysis. The c-Met knockdown in U266 cells decreased the average IC(50) of bortezomib, induced G0/G1 phase arrest, and increased caspase-mediated apoptosis in U266 cells exposed to bortezomib. In addition, c-Met knockdown decreased the level of cyclin D1 and increased the levels of p27 and cleaved caspase 3 and caspase 9. Moreover, the Akt/mTOR activity in U266 cells treated with bortezomib was downregulated upon c-Met knockdown and c-Met knockdown U266 cells recovered chemoresistance upon the overexpression of Akt and mTOR. Our data demonstrate that c-Met is a potential therapeutic target for multiple myeloma, and Akt/mTOR is a key signali...Continue Reading

References

May 11, 1989·Nature·S GiordanoP M Comoglio
Mar 12, 2002·British Journal of Haematology·Tsuyoshi IwasakiEizo Kakishita
May 28, 2004·Expert Opinion on Pharmacotherapy·Paul G Richardson
Oct 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Håkon HovMagne Børset
Oct 29, 2004·The New England Journal of Medicine·Robert A Kyle, S Vincent Rajkumar
Feb 24, 2005·Current Opinion in Oncology·Jean-Luc Harousseau
May 3, 2005·The Journal of Steroid Biochemistry and Molecular Biology·Nadja NazarovaPentti Tuohimaa
Jul 20, 2005·Best Practice & Research. Clinical Haematology·Paul G RichardsonKenneth C Anderson
Aug 13, 2005·Anti-cancer Drugs·Daniel Morgensztern, Howard L McLeod
Aug 25, 2005·Acta Oncologica·Joan BladéLaura Rosiñol
Sep 29, 2005·Hematology·Bo Björkstrand
Jun 30, 2006·Expert Opinion on Pharmacotherapy·Rakesh PopatJamie Cavenagh
Jan 25, 2008·Cancer Imaging : the Official Publication of the International Cancer Imaging Society·Conor D Collins
Mar 11, 2008·Haematologica·Randi Utne HoltMagne Børset
Feb 5, 2009·Molecular Cancer Therapeutics·Yunqing LiRoger Abounader
Oct 1, 2009·The FEBS Journal·Lindsey A Allan, Paul R Clarke
May 14, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·I CañadasE Arriola
Oct 15, 2010·European Journal of Haematology·Meletios A DimopoulosKenneth C Anderson

❮ Previous
Next ❯

Citations

Nov 21, 2013·Biomarker Research·Shuqing Lü, Jianmin Wang
Aug 14, 2012·Journal of Cellular Physiology·Ziv Radisavljevic
Dec 3, 2013·International Journal of Cancer. Journal International Du Cancer·Maria Beatrice MorelliMassimo Nabissi
Jan 24, 2014·British Journal of Haematology·Alberto RocciAntonio Palumbo
Oct 27, 2017·Cancer Metastasis Reviews·Jacqueline CloosGerrit Jansen
Jun 27, 2018·Cell Biochemistry and Function·Wenzhong QueShanghua Xu
Oct 26, 2018·Journal of Cellular and Molecular Medicine·Yibin ZhangJing Liu
Dec 6, 2018·CPT: Pharmacometrics & Systems Pharmacology·Vidya Ramakrishnan, Donald E Mager
Apr 11, 2018·The Journal of Pharmacology and Experimental Therapeutics·Vidya Ramakrishnan, Donald E Mager
May 15, 2015·Expert Review of Molecular Diagnostics·Manuela GambellaAlberto Rocci
Sep 21, 2018·Experimental and Therapeutic Medicine·Wenzhong QueShanghua Xu
Oct 22, 2019·Frontiers in Oncology·Phuong NguyenFukun Guo
May 17, 2018·Frontiers in Endocrinology·Mariah L Farrell, Michaela R Reagan
Jun 28, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michele MoschettaAngelo Vacca
Feb 11, 2021·Evidence-based Complementary and Alternative Medicine : ECAM·Jing ZhengJianda Hu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Apoptotic Caspases

Apoptotic caspases belong to the protease enzyme family and are known to play an essential role in inflammation and programmed cell death. Here is the latest research.